NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma

NCT04215471 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Oesophageal Squamous Cell Carcinoma

Interventions

DRUG: PD-L1 Antibody SHR-1316

Sponsor

Shanghai Zhongshan Hospital